EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Asprosin contributes to nonalcoholic fatty liver disease through regulating lipid accumulation and inflammatory response via AMPK signaling

Bo Zhang iD, Jinger Lu, Yuhua Jiang, Yan Feng

Immunity, Inflammation and Disease · 2023-08 · 11 (8)

DOI: 10.1002/iid3.947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 18.08.2023. Verfasst von Bo Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, The Affiliated People's Hospital of Ningbo University, Ningbo City, Zhejiang Province, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonalcoholic fatty liver disease (NAFLD) is a primary contributor to liver‐related morbidity and mortality. Asprosin has been reported to be implicated in NAFLD.

Aims

This work is to illuminate the effects of Asprosin on NAFLD and the possible downstream mechanism. Materials & Methods The weight of NAFLD mice induced by a high‐fat diet was detected. Quantitative reverse‐transcription polymerase chain reaction (RT‐qPCR) examined serum Asprosin expression. RT‐qPCR and western blot analysis examined Asprosin expression in mice liver tissues. Intraperitoneal glucose tolerance test (IPGTT) and intraperitoneal insulin tolerance test (IPITT) were implemented. Biochemical kits tested liver enzyme levels in mice serum and liver tissues. Hematoxylin and eosin staining evaluated liver histology. Liver weight was also tested and oil red O staining estimated lipid accumulation. RT‐qPCR and western blot analysis analyzed the expression of gluconeogenesis‐, fatty acid biosynthesis‐, fatty acid oxidation‐, and inflammation‐associated factors. Besides, western blot analysis examined the expression of AMP‐activated protein kinase (AMPK)/p38 signaling‐associated factors. In palmitic acid (PA)‐treated mice hepatocytes, RT‐qPCR and western blot analysis examined Asprosin expression. Lipid accumulation, gluconeogenesis, fatty acid biosynthesis, fatty acid oxidation, and inflammation were appraised again.

Results

Asprosin was overexpressed in the serum and liver tissues of NAFLD mice and PA‐treated mice hepatocytes. Asprosin interference reduced mice body and liver weight, improved glucose tolerance and diminished liver injury in vivo. Asprosin knockdown alleviated lipid accumulation and inflammatory infiltration both in vitro and in vivo. Additionally, Asprosin absence activated AMPK/p38 signaling and AMPK inhibitor Compound C reversed the impacts of Asprosin on lipid accumulation and inflammatory response.

Conclusion

Collectively, Asprosin inhibition suppressed lipid accumulation and inflammation to obstruct NAFLD through AMPK/p38 signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseAnimalsMiceAMP-Activated Protein KinasesInflammationFatty AcidsLipids

Stichwörter der Autor:innen

AMPK signalingAsprosininflammatory responselipid accumulationnonalcoholic fatty liver disease

Substanzen

AMP-Activated Protein KinasesFatty AcidsLipids

Autor:innen und Institutionen

  • Department of Infectious Disease, The Affiliated People's Hospital of Ningbo University, Ningbo City, Zhejiang Province, China.
  • Department of Endocrine, The Affiliated People's Hospital of Ningbo University, Ningbo City, Zhejiang Province, China.
  • Department of Digestive Blood Endocrinology, The 75th Group Army Hospital of PLA, Dali City, Yunnan Province, China.

ORCID-Profile: Bo Zhang

Zitieren

APA

Zhang, B., Lu, J., Jiang, Y., & Feng, Y. (2023). Asprosin contributes to nonalcoholic fatty liver disease through regulating lipid accumulation and inflammatory response via AMPK signaling. Immunity, Inflammation and Disease, 11(8). https://doi.org/10.1002/iid3.947

Vancouver

Zhang B, Lu J, Jiang Y, Feng Y. Asprosin contributes to nonalcoholic fatty liver disease through regulating lipid accumulation and inflammatory response via AMPK signaling. Immunity, Inflammation and Disease. 2023;11(8). doi:10.1002/iid3.947

BibTeX
@article{Zhang2023,
  author = {Zhang, Bo and Lu, Jinger and Jiang, Yuhua and Feng, Yan},
  title = {Asprosin contributes to nonalcoholic fatty liver disease through regulating lipid accumulation and inflammatory response via AMPK signaling},
  journal = {Immunity, Inflammation and Disease},
  year = {2023},
  volume = {11},
  number = {8},
  doi = {10.1002/iid3.947}
}
Kostenlos starten →